Rapid treatment of "wearing off" in Parkinson's disease

Neurology

Volumn 62, Issue 6 SUPPL. 4, 2004, Pages

  Swope, David M ^a  

^a LOMA LINDA UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AMANTADINE; ANTIPARKINSON AGENT; APOMORPHINE; BENSERAZIDE; CATECHOL METHYLTRANSFERASE INHIBITOR; DOPA DECARBOXYLASE INHIBITOR; DOPAMINE RECEPTOR STIMULATING AGENT; LEVODOPA; TRIMETHOBENZAMIDE;

ACTIVE TRANSPORT; AKINESIA; BLOOD BRAIN BARRIER; DISEASE ASSOCIATION; DISEASE COURSE; HUMAN; INDIVIDUALIZATION; INTESTINE ABSORPTION; MOTOR DYSFUNCTION; ON OFF PHENOMENON; PARKINSON DISEASE; PRACTICE GUIDELINE; PRIORITY JOURNAL; REVIEW; SIDE EFFECT; STOMACH EMPTYING;

EID: 1842575734     PISSN: 00283878     EISSN: None     Source Type: Journal    
DOI: 10.1212/wnl.62.6_suppl_4.s27     Document Type: Review

References (30)

1. Jankovic J. Complications and limitations of drug therapy for Parkinson's disease. Neurology 2000;55(suppl 6):S2-6.
2. Koller WC. Management of motor fluctuations in Parkinson's disease. Eur Neurol 1996;36(suppl 1):43-48.
3. Quinn N. Classification of fluctuations in patients with Parkinson's disease. Neurology 1998;51(suppl 2):S25-29.
4. Koller WC, Silver DE, Lieberman AN. An algorithm for the management of Parkinson's disease. Neurology 1994;44(suppl 10):S1-52.
5. Olanow CW, Koller WC. An algorithm (decision tree) for the management of Parkinson's disease: treatment guidelines. Neurology 1998; 50(suppl 3):S1-57.
6. Contin M, Riva R, Martinelli P, Cortelli P, Albani F, Baruzzi A. Concentration-effect relationship of levodopa-benserazide dispersible formulation versus standard form in the treatment of complicated motor response fluctuations in Parkinson's disease. Clin Neuropharmacol 1999;22:351-355.
7. Kurth MC. Using liquid levodopa in the treatment of Parkinson's disease. A practical guide. Drugs Aging 1997;10:332-340.
8. Durso R, Evans JE, Josephs E, et al. Variable absorption of carbidopa affects both peripheral and central levodopa metabolism. J Clin Pharmacol 2000;40:854-860.
9. Dewey RB. Management of motor complications in Parkinson's disease. This supplement.
10. Djaldetti R, Atlas D, Melamed E. Effect of subcutaneous administration of levodopa ethyl ester, a soluble prodrug of levodopa, on dopamine metabolism in rodent striatum: implication for treatment of Parkinson's disease. Clin Neuropharmacol 1996;19:65-71.
11. Stocchi F, Barbato L, Bramante L, Bonamartini A, Ruggieri S. The clinical efficacy of a single afternoon dose of levodopa methyl ester: A double-blind cross-over study versus placebo. Funct Neurol 1994;9:259-264.
12. Stocchi F, Barbato L, Bramante L, Nordera G, Vacca L, Ruggieri S. Fluctuating parkinsonism: a pilot study of single afternoon dose of levodopa methyl ester. J Neurol 1996;243:377-380.
13. Djaldetti R, Rosmarin V, Ziv I, Melamed E. The pharmacokinetic profile of the "first ever" oral dose of levodopa in de novo patients with Parkinson's disease. Clin Neuropharmacol 2001;24:95-98.
14. Kao HD, Traboulsi A, Itoh S, Dittert L, Hussain A. Enhancement of the systemic and CNS specific delivery of L-dopa by the nasal administration of its water soluble prodrugs. Pharmacol Res 2000;17:978-984.
15. Iwase H, Sudo J, Terui J, et al. Transdermal absorption of L-dopa from a new system composed of two separate layers of L-dopa and hydrogel in rats. Drug Dev Ind Pharm 2000;26:755-759.
16. Deleu D, Northway M, Hanssens Y. Clinical pharmacokinetic and pharmacodynamic properties of drugs used in the treatment of Parkinson's disease. Clin Pharmacokinet 2002;41:261-309.
17. Cedarbaum J, Kutt H, McDowell F. A pharmacokinetic and pharmacodynamic comparison of Sinemet CR (50/200) and standard Sinemet (25/100). Neurology 1989;39(suppl 2):38-44.
18. LeWitt P, Nelson M, Berchou R, et al. Controlled-release carbidopa/levodopa (Sinemet 50/200 CR4): clinical and pharmacokinetic studies. Neurology 1989;39(suppl 2):45-53.
19. Contin M, Riva R, Martinelli P, Cortelli P, Albani F, Baruzzi A. Longitudinal monitoring of the levodopa concentration-effect relationship in Parkinson's disease. Neurology 1994;44:1287-1292.
20. Kaakkola S. Clinical pharmacology, therapeutic use and potential of COMT inhibitors in Parkinson's disease. Drugs 2000;59:1233-1250.
21. Nutt J, Woodward W, Beckner R, et al. Effect of peripheral catechol-O-methyltransferase inhibition on the pharmacokinetics and pharmacodynamics of levodopa in parkinsonian patients. Neurology 1994;44:913-919.
22. Jorga K. Pharmacokinetics, pharmacodynamics, and tolerability of tolcapone: a review of early studies in volunteers. Neurology 1998; 50(suppl 5):S31-38.
23. Piccini P, Brooks D, Korpela K, Pavese N, Karlsson M, Gordin A. The catechol-O-methyltransferase (COMT) inhibitor entacapone enhances the pharmacokinetic and clinical response to Sinemet CR in Parkinson's disease. J Neurol Neurosurg Psychiatry 2000;68:589-594.
24. Kurth M, Tetrud J, Irwin I, Lyness W, Langston J. Oral levodopa/ carbidopa solution versus tablets in Parkinson's patients with severe fluctuations: a pilot study. Neurology 1993;43:1036-1039.
25. Metman LV, Hoff J, Mouradian MM, Chase TN. Fluctuations in plasma levodopa and motor responses with liquid and tablet levodopa/carbidopa. Mov Disord 1994;9:463-465.
26. Pappert EJ, Goetz CG, Niederman F, Ling ZD, Stebbins GT, Carvey PM. Liquid levodopa/carbidopa produces significant improvement in motor function without dyskinesia exacerbation. Neurology 1996;47: 1493-1495.
27. Nahata MC, Morosco RS, Leguire LE. Development of two stable oral suspensions of levodopa-carbidopa for children with amblyopia. J Pediatr Ophthalmol Strabismus 2000;37:333-337.
28. Neef C, Van Laar T. Pharmacokinetic-pharmacodynamic relationships of apomorphine in patients with Parkinson's disease. Clin Pharmacokinet 1999;37:257-271.
29. Bowron A. Practical considerations in the use of apomorphine injectable. Neurology 2004;62(Suppl 4):S32-S36.
30. Poewe W. Clinical aspects of motor fluctuations in Parkinson's disease. Neurology 1994;44(suppl 6):S6-9.